Business Wire

Elixir Medical Announces Outstanding 24-month Data for DynamX Coronary Bioadaptor System, Demonstrating Strong Safety With No Target Lesion Revascularization, Myocardial ...

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor ...
WREG

Roof Dynamx Expands Regional Presence with Innovative Roofing Services

Roof Dynamx has consistently demonstrated its expertise in delivering high-quality roofing solutions for both residential and commercial properties. With a commitment to superior craftsmanship, the ...
Business Wire

Elixir Medical Announces Outstanding 9 and 12-Month Clinical and Imaging Results for the Transformational DynamX™ Bioadaptor at EuroPCR

MILPITAS, Calif. & PARIS--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced at EuroPCR ...
Seeking Alpha

EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX ® compared to DES— —Significantly lower ...